These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 22059643)

  • 21. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidisciplinary management of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Escolar ML; Giugliani R; Guffon NH; Harmatz P; Kamin W; Kampmann C; Koseoglu ST; Link B; Martin RA; Molter DW; Muñoz Rojas MV; Ogilvie JW; Parini R; Ramaswami U; Scarpa M; Schwartz IV; Wood RE; Wraith E
    Pediatrics; 2009 Dec; 124(6):e1228-39. PubMed ID: 19901005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
    Beck M
    Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy.
    Filippon L; Vanzin CS; Biancini GB; Pereira IN; Manfredini V; Sitta A; Peralba Mdo C; Schwartz IV; Giugliani R; Vargas CR
    Mol Genet Metab; 2011 Jun; 103(2):121-7. PubMed ID: 21420339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.
    Schulze-Frenking G; Jones SA; Roberts J; Beck M; Wraith JE
    J Inherit Metab Dis; 2011 Feb; 34(1):203-8. PubMed ID: 20978944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan.
    Nakamura K; Sakai N; Hossain MA; Eisengart JB; Yamamoto T; Tanizawa K; So S; Schmidt M; Sato Y
    Orphanet J Rare Dis; 2024 Mar; 19(1):104. PubMed ID: 38454486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.
    Lampe C; Bosserhoff AK; Burton BK; Giugliani R; de Souza CF; Bittar C; Muschol N; Olson R; Mendelsohn NJ
    J Inherit Metab Dis; 2014 Sep; 37(5):823-9. PubMed ID: 24596019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice.
    Akiyama K; Shimada Y; Higuchi T; Ohtsu M; Nakauchi H; Kobayashi H; Fukuda T; Ida H; Eto Y; Crawford BE; Brown JR; Ohashi T
    Mol Genet Metab; 2014 Feb; 111(2):139-46. PubMed ID: 24100247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).
    Martin R; Beck M; Eng C; Giugliani R; Harmatz P; Muñoz V; Muenzer J
    Pediatrics; 2008 Feb; 121(2):e377-86. PubMed ID: 18245410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hunter syndrome follow-up after 1 year of enzyme-replacement therapy.
    Puiu M; Chirita-Emandi A; Dumitriu S; Arghirescu S
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23307460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases.
    Sohn YB; Choi EW; Kim SJ; Park SW; Kim SH; Cho SY; Jeong SI; Huh J; Kang IS; Lee HJ; Paik KH; Jin DK
    Am J Med Genet A; 2012 Jan; 158A(1):90-6. PubMed ID: 22105882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy for the management of the mucopolysaccharidoses.
    Wraith JE
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S63-5. PubMed ID: 20040314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
    Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
    Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples.
    Dean CJ; Bockmann MR; Hopwood JJ; Brooks DA; Meikle PJ
    Clin Chem; 2006 Apr; 52(4):643-9. PubMed ID: 16497940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice.
    Sohn YB; Lee J; Cho SY; Kim SJ; Ko AR; Nam MH; Jin DK
    Am J Med Genet A; 2013 May; 161A(5):1036-43. PubMed ID: 23529876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.
    Wakabayashi T; Shimada Y; Akiyama K; Higuchi T; Fukuda T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Hum Gene Ther; 2015 Jun; 26(6):357-66. PubMed ID: 25761450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Early enzyme replacement therapy - hope for patients with mucopolysaccharidosis Type II].
    Orchel-Szastak K; Ptak K; Hrnciar K; Pilch B; Kania U; Bik-Multanowski M
    Pediatr Endocrinol Diabetes Metab; 2017; 23(2):111-116. PubMed ID: 29073295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical practice guideline for the management of Hunter syndrome. Hunter España working group].
    Guillén-Navarro E; Blasco AJ; Gutierrez-Solana LG; Couce ML; Cancho-Candela R; Lázaro P;
    Med Clin (Barc); 2013 Nov; 141(10):453.e1-13. PubMed ID: 24060500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.